Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

4 DNA sequencing predictions for 2023  

By Brian Buntz | December 10, 2022

DNA

Image courtesy of Pixabay

Continued innovations in bioinformatics paired with the falling cost of DNA sequencing are poised to spur research breakthroughs in 2023.

To gauge how the DNA sequencing field is likely to evolve, we reached out to Logan Zinser, SVP, finance, Element Biosciences and Keith Robison, principal engineer, NGS Computational Biology, Ginkgo Bioworks. In the following feature, the two muse on themes ranging from the growing availability of next-generation sequencing and multiplex testing.

1. Falling DNA sequencing costs will empower the data-savvy

As the costs of DNA sequencing continue to fall, companies will do more sequencing.

“At Element, we are enabling our customers to generate a tremendous amount of high-quality genomic data at an unprecedented price, so the challenge shifts toward making sense of those data,” Zinser said. “Working with our customers and partners, we are leveraging advances in machine learning and artificial intelligence to assist in interpreting the big data generated by our sequencers.”

Keith Robison

Keith Robison

Robinson had a similar take. “The dropping cost per base of DNA sequence will be most valuable to those who can extract a large amount of valuable data from each sequencing experiment and apply that to their problem space,” he said.

The falling cost of sequencing will make it possible to sequence more individual samples, examine more replicates of the same sample, explore more conditions in a process and go deeper into an environmental sample, Robinson added. “But more data isn’t useful unless you have the computational approaches to convert raw data into insights.”

2. Democratization of next-generation sequencing

For the first time in more than a decade, next-generation sequencing (NGS) users have “a real alternative to the dominant sequencing platform,” Zinser said. “They won’t have to spend more to get a lower cost per unit of data.”

Zinser says that NGS users with lower sample volumes now have an opportunity to buy a sequencer that matches the pricing afforded to high-volume users. “In 2023 and beyond, we expect to see the playing field even out, allowing for less sequencing centralization and more democratization and control of samples and the resulting data,” he said. “In 2023, we are moving forward rapidly with innovations in sequencing that will reduce run times and enable even more applications.”

3. Multiplex testing gains ground

Multiplex tests can analyze samples for multiple pathogens at the same time, measuring populations of molecules in a sample. “The numbers of each sequence tell you something, such as ‘How strongly expressed is each gene’ or Which of my strains is the best-performing at synthesizing my target?” Zinser said.

Logan Zinser

Logan Zinser

The pandemic has spurred an increase in demand to apply multiplex testing to COVID-19, RSV and influenza, enabling researchers to differentiate between multiple viruses in a single assay. The CDC, for instance, has developed a multiplex assay that is a real-time reverse-transcription polymerase chain reaction test that can simultaneously detect and differentiate between influenza A, influenza B and SARS-CoV-2.

In general, setting up multiplex strain tests requires ingenuity in experiment design, Zinser said. Properly designing such tests enables linking biological processes to DNA sequence barcodes. In addition, such tests require skill at creating large numbers of strains and diligence in correctly executing the experimental protocol and downstream data analysis.

4. Spatial biology helps prove utility for genomics

Nascent applications such as spatial biology will continue to grow and prove utility for the genomics market, Zinser noted. “This will lead to further research findings and applications for NGS to displace legacy solutions such as Sanger sequencing,” he explained. “In the translational and clinical space, we are seeing continued expansion of NGS as a first-line test in areas such as oncology.”

Element Biosciences continues to observe an increased use of NGS and its pairing as a companion diagnostic in drug therapy selection.


Filed Under: Data science, Omics/sequencing
Tagged With: DNA sequencing
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

How Thermo Fisher’s KingFisher PlasmidPro crunches hours of plasmid prep to 5 minutes hands-on
NBC 2025 Preview: Inside CheckImmune’s playbook for cell-specific drug insights
A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
CRISPR
Why the plasticity of biology may be AI’s hardest challenge 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE